2.要約四半期連結財務諸表及び主な注記

(1)要約四半期連結財政状態計算書

 

 

 

 

 

(単位:百万円)

 

 

 

前連結会計年度末

(2025年3月31日)

 

当第3四半期連結会計期間

(2025年12月31日)

資産

 

 

 

 

 

流動資産

 

 

 

 

 

現金及び現金同等物

 

 

55,241

 

60,771

営業債権及びその他の債権

 

 

42,292

 

53,661

棚卸資産

 

 

42,500

 

48,614

その他の金融資産

 

 

3,244

 

2,298

その他の流動資産

 

 

6,461

 

6,177

流動資産合計

 

 

149,740

 

171,523

非流動資産

 

 

 

 

 

有形固定資産

 

 

34,531

 

34,652

無形資産

 

 

48,315

 

48,078

使用権資産

 

 

2,781

 

2,544

その他の金融資産

 

 

39,492

 

63,407

繰延税金資産

 

 

5,597

 

4,767

その他の非流動資産

 

 

3,177

 

3,134

非流動資産合計

 

 

133,897

 

156,584

資産合計

 

 

283,637

 

328,108

 

 

 

 

 

 

 

 

 

 

 

 

 

(単位:百万円)

 

 

 

前連結会計年度末

(2025年3月31日)

 

当第3四半期連結会計期間

(2025年12月31日)

負債及び資本

 

 

 

 

 

負債

 

 

 

 

 

流動負債

 

 

 

 

 

営業債務及びその他の債務

 

 

16,857

 

18,908

その他の金融負債

 

 

305

 

1,004

リース負債

 

 

1,348

 

910

未払法人所得税

 

 

4,705

 

3,102

その他の流動負債

 

 

7,100

 

6,482

流動負債合計

 

 

30,316

 

30,408

非流動負債

 

 

 

 

 

その他の金融負債

 

 

233

 

234

リース負債

 

 

1,374

 

1,637

退職給付に係る負債

 

 

4,313

 

4,431

繰延税金負債

 

 

-

 

7,140

その他の非流動負債

 

 

59

 

59

非流動負債合計

 

 

5,980

 

13,503

負債合計

 

 

36,297

 

43,911

資本

 

 

 

 

 

資本金

 

 

5,174

 

5,174

資本剰余金

 

 

4,491

 

4,529

利益剰余金

 

 

222,640

 

242,446

自己株式

 

 

2,459

 

2,440

その他の資本の構成要素

 

 

17,181

 

34,169

親会社の所有者に帰属する持分合計

 

 

247,028

 

283,878

非支配持分

 

 

312

 

317

資本合計

 

 

247,340

 

284,196

負債及び資本合計

 

 

283,637

 

328,108

 

E0093145160日本新薬株式会社Nippon Shinyaku Co.,Ltd.四半期第3号参考様式 [IFRS](連結)IFRStrueCTE2025-04-012025-12-31Q32026-03-312024-04-012024-12-312025-03-311falsefalsefalse451602024-03-31451602025-03-31451602024-04-012024-12-31451602024-12-31451602025-04-012025-12-31451602025-12-31451602024-04-012024-12-31tse-qcediffr-45160:FunctionalFoodsReportableSegmentMember451602024-04-012024-12-31jpcrp_cor:ReconcilingItemsMember451602025-04-012025-12-31jpcrp_cor:ReportableSegmentsMember451602025-04-012025-12-31tse-qcediffr-45160:MedicineReportableSegmentMember451602025-04-012025-12-31tse-qcediffr-45160:FunctionalFoodsReportableSegmentMember451602025-04-012025-12-31jpcrp_cor:ReconcilingItemsMember451602024-04-012024-12-31tse-qcediffr-45160:MedicineReportableSegmentMember451602024-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-03-31jpigp_cor:ShareCapitalIFRSMember451602024-03-31jpigp_cor:CapitalSurplusIFRSMember451602024-03-31jpigp_cor:RetainedEarningsIFRSMember451602024-03-31jpigp_cor:TreasurySharesIFRSMember451602024-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-03-31jpigp_cor:NonControllingInterestsIFRSMember451602025-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-03-31jpigp_cor:ShareCapitalIFRSMember451602025-03-31jpigp_cor:CapitalSurplusIFRSMember451602026-02-09451602025-03-31jpigp_cor:RetainedEarningsIFRSMember451602025-03-31jpigp_cor:TreasurySharesIFRSMember451602025-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-03-31jpigp_cor:NonControllingInterestsIFRSMember451602024-04-012024-12-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-04-012024-12-31jpigp_cor:ShareCapitalIFRSMember451602024-04-012024-12-31jpigp_cor:CapitalSurplusIFRSMember451602024-04-012024-12-31jpigp_cor:RetainedEarningsIFRSMember451602024-04-012024-12-31jpigp_cor:TreasurySharesIFRSMember451602024-04-012024-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-04-012024-12-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-04-012024-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-04-012024-12-31jpigp_cor:NonControllingInterestsIFRSMember451602024-12-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-12-31jpigp_cor:ShareCapitalIFRSMember451602024-12-31jpigp_cor:CapitalSurplusIFRSMember451602024-12-31jpigp_cor:RetainedEarningsIFRSMember451602024-12-31jpigp_cor:TreasurySharesIFRSMember451602024-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-12-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-12-31jpigp_cor:NonControllingInterestsIFRSMember451602025-04-012025-12-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-04-012025-12-31jpigp_cor:ShareCapitalIFRSMember451602025-04-012025-12-31jpigp_cor:CapitalSurplusIFRSMember451602025-04-012025-12-31jpigp_cor:RetainedEarningsIFRSMember451602025-04-012025-12-31jpigp_cor:TreasurySharesIFRSMember451602025-04-012025-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-04-012025-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-04-012025-12-31jpigp_cor:NonControllingInterestsIFRSMember451602025-12-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-12-31jpigp_cor:ShareCapitalIFRSMember451602025-12-31jpigp_cor:CapitalSurplusIFRSMember451602025-12-31jpigp_cor:RetainedEarningsIFRSMember451602025-12-31jpigp_cor:TreasurySharesIFRSMember451602025-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-12-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-12-31jpigp_cor:NonControllingInterestsIFRSMember451602025-04-012025-12-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-04-012024-12-31jpcrp_cor:ReportableSegmentsMemberiso4217:JPYxbrli:sharesiso4217:JPYxbrli:pure